Heme oxygenase and the cardiovascular-renal system.
Heme oxygenase (HO) has been shown to be important for attenuating the overall production of reactive oxygen species (ROS) through its ability to degrade heme and to produce carbon monoxide (CO), biliverdin/bilirubin, and the release of free iron. Excess free heme catalyzes the formation of ROS, which may lead to endothelial cell (EC) dysfunction as seen in numerous pathological conditions including hypertension and diabetes, as well as ischemia/reperfusion injury. The upregulation of HO-1 can be achieved through the use of pharmaceutical agents, such as metalloporphyrins and some HMG-CoA reductase inhibitors. Among other agents, atrial natriretic peptide and donors of nitric oxide (NO) are important modulators of the heme-HO system, either through induction of HO-1 or the biological activity of its products. Gene therapy and gene transfer, including site- and organ-specific targeted gene transfer, have become powerful tools for studying the potential role of HO-1/HO-2 in the treatment of various cardiovascular diseases as well as diabetes. HO-1 induction by pharmacological agents or gene transfer of human HO-1 into endothelial cells (ECs) in vitro increases cell-cycle progression and attenuates Ang II, TNF-, and heme-mediated DNA damage; administration in vivo acts to correct blood pressure elevation following Ang II exposure. Moreover, site-specific delivery of HO-1 to renal structures in spontaneously hypertensive rats (SHR), specifically to the medullary thick ascending limb of the loop of Henle (mTALH), has been shown to normalize blood pressure and provide protection to the mTAL against oxidative injury. In other cardiovascular situations, delivery of human HO-1 to hyperglycemic rats significantly lowers superoxide (O(2)(-)) levels and prevents EC damage and sloughing of vascular EC into the circulation. In addition, administration of human HO-1 to rats in advance of ischemia/reperfusion injury considerably reduces tissue damage. The ability to upregulate HO-1 through pharmacological means or through the use of gene therapy may offer therapeutic strategies for cardiovascular disease in the future. This review discusses the implications of HO-1 delivery during the early stages of cardiovascular system injury or in early vascular pathology and suggests that pharmacological agents that regulate HO activity or HO-1 gene delivery itself may become powerful tools for preventing the onset or progression of certain cardiovascular pathologies.
Abraham
Nader G
NG
New York Medical College, Basic Science Building, Valhalla, NY 10595, USA. Nader_abraham@nymc.edu
Kappas
Attallah
A
D000800:Angioplasty, Balloon; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D016718:Arachidonic Acid / Q000378:metabolism; D001663:Bilirubin / Q000096:biosynthesis; D002248:Carbon Monoxide / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000503:physiopathology*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology; D042783:Endothelial Cells / Q000502:physiology*; D004790:Enzyme Induction; D006419:Heme Oxygenase (Decyclizing) / Q000235:genetics / Q000502:physiology*; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis; D007668:Kidney / Q000201:enzymology*; D009203:Myocardial Infarction / Q000188:drug therapy; D011110:Polymorphism, Genetic; D014664:Vasodilation
D000975:Antioxidants; D007527:Isoenzymes; D016718:Arachidonic Acid; D002248:Carbon Monoxide; D003577:Cytochrome P-450 Enzyme System; D006419:Heme Oxygenase (Decyclizing); D001663:Bilirubin